Four cell lines were used in this study. Two KRAS dependent AML derived cell lines, NOMO-1 and SKM-1, were compared with two KRAS independent lines, THP-1 and U937, to test the hypothesis that inhibition of STK33 with the probe compounds ML280 and ML281 would lead to KRAS dependent cell death as described (18). All cell lines were the kindly provided by Gary Gilliland (Bringham and Women's Hospital, Boston).
1. Add 2.0 µl assay buffer to the last two columns of 1536-well, white Aurora highbase assay plate (containing 2.5 nl 10 mM compound or DMSO) using Combi-nL dispenser (Thermo). 2. Add 2.0 µl STK33/MBP to all but last two columns of 1536-well assay ready plates (containing 2.5 nL 10 mM compound/well). 3. Incubate 15 minutes at room temperature. 4. Add 0.5 µl ATP/Mg/well to full plate. Incubate 60 minutes followed by luminescent readout using the ADP-Glo Assay kit per the manufacturer's directions 5. Add 2.5 µl/well ADP Glo Reagent I (Promega). Incubate 40 minutes. 6. Add 5 µl/well ADP Glo Reagent II (Promega). Incubate 30 minutes. 7. Read luminescence (15 sec integration time) on ViewLux CCD-based imaging plate reader (Perkin Elmer).
384-well Plate Assay
1. Add 20 µl assay buffer to the last column of the 384-well, white Aurora assay plate using Combi dispenser (Thermo). 2. Add 20 µl STK33/MBP to all but last column. 3. Using a pintool, transfer 25 nl compound in DMSO stock solution into assay plate. 4. Incubate 15 minutes at room temperature. 5. Add 5 µl ATP/Mg/well to full plate. Incubate 60 minutes. 6. Add 25 µl/well ADP Glo Reagent I (Promega). Incubate 40 minutes. 7. Add 50 µl/well ADP Glo Reagent II (Promega). Incubate 30 minutes. 8. Read luminescence (0.1 sec integration time) on Envision plate reader (Perkin Elmer).
PKA Kinase Caliper Assay:
Inhibition of PKA activity was measured using a recombinant His-tagged PKA catalytic fragment and a fluorescently-labeled peptide substrate in an end-point readout assay of compounds of interest at various concentrations. In a 384-well polypropylene plates, purified PKA (20 µl/well) was mixed together with 15 µM ATP, 15 mM MgAc 2 in assay buffer (10 mM MOPS pH 7, 300 µM EDTA, 0.5 % (V/V) Glycerol, 0.001% (V/V) Brij-35). Using a pin tool, 25 nl of compound dilutions in DMSO were added. Next, 5 µl of 5 nM PKA and 15 µM of Peptide 21 in assay buffer were added. The plates were incubated at room temperature for 1 hour followed by the addition of 1.5 nM PKA, 3 µM Peptide 21 (Fluorescent Peptide Substrate), and 12 µM ATP (final conditions). The enzymatic reaction was allowed to proceed, and then was stopped by the addition of the 10 µl of 75 mM metal chelator EDTA. Percent (%) conversion of substrate to product (i.e., peptide to hosphor-peptide) was quantitated using a capillary electrophoresis lab-on-a-chip (LOC) device (Caliper EZReader with 12-channel Sipper chip, Caliper Life Sciences) at the conditions specified by the manufacturer for Peptide 21. 
Assay Buffer

Aurora B Kinase Radiolabel Binding Assay:
The Aurora B (AurB) kinase assay was outsourced to Millipore Corporation. The inhibition of AurB activity was measured in response to various concentrations of the compound of interest based on a filter-binding isotopic assay. 
Cell Based Assays:
NOMO-1, SKM-1, THP-1, U937 were kindly provided by Gary Gilliland (Brigham and Women's Hospital, Boston). All cell lines were maintained under the manufacturer's recommended standard conditions. Cells were plated in 384-well plates at optimized densities and incubated overnight prior to treatment. Compounds were added to cells using a CyBio Well Vario after which cells were cultured under standard condition for 72 h. Cell viability was measured using CellTiter Glo luminescence (Promega) and readout using an LJL Biosystems Analyst microplate reader. Raw numbers were the normalized to the median of the DMSO treated wells for each plate.
Experimental Procedures for Analytical Assays:
Solubility Solubility was determined in phosphate buffered saline (PBS) pH 7.4 with 1% DMSO. Each compound was prepared in duplicate at 100 µM in both 100% DMSO and PBS with 1% DMSO. Compounds were allowed to equilibrate at room temperature with a 250-rpm orbital shake for 24 hours. After equilibration, samples were analyzed by UPLC-MS (Waters, Milford, MA) with compounds detected by SIR detection on a single quadrupole mass spectrometer. The DMSO samples were used to create a two-point calibration curve to which the response in PBS was fit.
Plasma Protein Binding
Plasma protein binding was determined by equilibrium dialysis using the Rapid Equilibrium Dialysis (RED) device (Pierce Biotechnology, Rockford, IL) for both human and mouse plasma. Each compound was prepared in duplicate at 5 µM in plasma (0.95% acetonitrile, 0.05% DMSO) and added to one side of the membrane (200 µl) with PBSpH 7.4 added to the other side (350 µl). Compounds were incubated at 37 o C for 5 hours with a 250-rpm orbital shake. After incubation, samples were analyzed by UPLC-MS (Waters, Milford, MA) with compounds detected by SIR detection on a single quadrupole mass spectrometer.
Plasma Stability
Plasma stability was determined at 37 o C at 5 hours in both human and mouse plasma. Each compound was prepared in duplicate at 5 µM in plasma diluted 50/50 (v/v) with PBS pH 7.4 (0.95% acetonitrile, 0.05% DMSO). Compounds were incubated at 37 o C for 5 hours with a 250-rpm orbital shake with time points taken at 0 and 5 hours. Samples were analyzed by UPLC-MS (Waters, Milford, MA) with compounds detected by SIR detection on a single quadrupole mass spectrometer.
Experimental Procedures for the Synthesis of the Probes:
General details. All reagents and solvents were purchased from commercial vendors and used as received. Unless otherwise indicated, NMR data were collected at 25°C. Flash chromatography was performed using 40-60 μm Silica Gel (60 Å mesh) on a Teledyne Isco Combiflash Rf system. Tandem Liquid Chromatography/Mass Spectrometry (LC/MS) was performed on a Waters 2795 separations module and 3100 mass detector. Analytical thin layer chromatography (TLC) was performed on EM Reagent 0.25 mm silica gel 60-F plates. Visualization was accomplished with ultraviolet (UV) light and aqueous potassium permanganate (KMnO 4 ) stain followed by heating.
Synthesis of ML281 (7r):
Scheme S1. Synthesis of ML281 5-Isopropyl-1-(thiophene-2-carbonyl)indoline-2,3-dione (S1): 5-Isopropylindoline-2,3-dione (100 mg, 0.529 mmol) was dissolved in DCM under inert atmosphere and Hunig's base (0.184 ml, 1.057 mmol) was added. The mixture was cooled to 0 o C, and thiophene-2-carbonyl chloride (0.062 ml, 0.581 mmol) was added dropwise. After 10 minutes at 0 o C, the mixture was left to warm to room temperature overnight. LCMS showed selective formation of the desired product, and the mixture was extracted using DCM/aq.HCl 0.1N. Concentration of the organic phase afforded 159 mg of 6r (0.529 mmol, 100%) which was used in the next step without further purification. LRMS [M + H] + : 300.34. -2-(3-oxo-3 ,4-dihydroquinoxalin-2-yl)phenyl)thiophene-2-carboxamide (7r): 5-Isopropyl-1-(thiophene-2-carbonyl)indoline-2,3-dione 6r (159 mg, 0.529 mmol) was dissolved in a mixture of acetic acid/water 10/1 (2 ml), heated at 80 o C, and benzene-1,2-diamine (61 mg, 0.567 mmol) was added. After 5 minutes, a yellow precipitate was observed and heating was continued for 15 minutes. After cooling the mixture to room temperature, filtration followed by successive washing with acetic acid (3 ml), acetic acid/water 1/1 (5 ml), and water (10 ml) afforded 7r, 133 mg as a yellow powder (0.341 mmol, 64% 34, 156.43, 154.62, 143.88, 139.83, 134.12, 132.05, 131.87, 131.42, 130.35, 129.01, 128.61, 128.41, 128.21, 127.90, 127.69, 124.08, 123.40, 115.22, 32.94, 23.82 
N-(4-isopropyl
Experimental Procedure for the synthesis of Amgen Compound 1:
The Amgen compound 1 was synthesized in our group in order to be used as the positive control throughout the project (Scheme S2). Briefly, 1-methylpiperazine was condensed with 1-chloro-2-methoxy-4-nitrobenzene to afford the intermediate S2, which was hydrogenated to the corresponding aniline S3. In parallel, 6-chloro-1H-pyrazolo [3,4-d] pyrimidine was coupled with 4-methoxyphenylboronic acid in the presence of copper (II) acetate and pyridine to afford intermediate S4, which was characterized by X-ray crystallography ( Figure S1 ). The crystal structure confirmed that the Cu(II) mediated Narylation proceeded chemoselectively to deliver compound S4. Intermediate S4 was then condensed with the aniline S3 in the presence of hydrochloric acid to afford Compound 
1-(2-Methoxy-4-nitrophenyl)-4-methylpiperazine (S2):
1-(2-methoxy-4-nitrophenyl)-4-methylpiperazine (500 mg, 2.67 mmol) and 1-methylpiperazine (5.9 ml, 53.3 mmol) were heated at 100 o C for 20 h. After cooling to room temperature, the excess methylpiperazine was evaporated and 20 ml of HCl 1M was added. The aqueous phase was washed with DCM (2 times 20 ml), basified using NaOH 2M (15 ml), and reextracted using DCM (3 times 30 ml). 153.57, 152.53, 136.66, 134.99, 134.15, 132.13, 123.05, 118.39, 114.19, 111.50, 103.86, 55.57, 55.26, 50.65, 45.93 
